Home > Compound List > Product Information
Quinaprilat hydrate_Molecular_structure_CAS_82768-85-2(anhydrous))
Click picture or here to close

Quinaprilat hydrate

Catalog No. Q0264 Name Sigma Aldrich
CAS Number 82768-85-2(anhydrous) Website http://www.sigmaaldrich.com
M. F. C23H28N2O6 Telephone 1-800-521-8956
M. W. 428.47822 Fax
Purity ≥98% (HPLC) Email
Storage Chembase ID: 155036

SYNONYMS

IUPAC name
(3S)-2-[(2S)-2-{[(1S)-1-carboxy-3-phenylpropyl]amino}propanoyl]-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid hydrate
IUPAC Traditional name
quinaprilat hydrate
Synonyms
(3S)-2-[(2S)-2-[[(1S)-1-Carboxy-3-phenylpropyl]amino]-1-oxopropyl]-1,2,3,4-tetrahydro-3-isoquinolinecarboxylic acid hydrate

DATABASE IDS

CAS Number 82768-85-2(anhydrous)
MDL Number MFCD08060097

PROPERTIES

Empirical Formula (Hill Notation) C23H26N2O5 · xH2O
Purity ≥98% (HPLC)
Apperance white to tan powder
Optical Rotation [α]/D +16 to +23 ( C=1, MeOH)
Solubility DMSO: ≥23 mg/mL
GHS Pictograms GHS06
GHS Pictograms GHS09
GHS Signal Word Danger
GHS Hazard statements H301-H400
European Hazard Symbols Toxic Toxic (T)
European Hazard Symbols Nature polluting Nature polluting (N)
MSDS Link Download
GHS Precautionary statements P273-P301 + P310
Risk Statements 25-50
Safety Statements 45-61
Storage Temperature 2-8°C
German water hazard class 3

DETAILS

Description (English)
Biochem/physiol Actions
Quinaprilat is the active metabolite of Quinapril. It is an angiotensin converting enzyme (ACE) inhibitor, an antihypertensive used in treatment of congestive heart failure. Quinaprilat has high affinity to tissue ACE, and has been shown to improve impaired flow-dependent (endothelium-mediated) dilation (FDD) in patients with chronic heart failure compared to other ACE inhibitors with low affinity for tissue ACE.
Description (简体中文)
Biochem/physiol Actions
Quinaprilat is the active metabolite of Quinapril. It is an angiotensin converting enzyme (ACE) inhibitor, an antihypertensive used in treatment of congestive heart failure. Quinaprilat has high affinity to tissue ACE, and has been shown to improve impaired flow-dependent (endothelium-mediated) dilation (FDD) in patients with chronic heart failure compared to other ACE inhibitors with low affinity for tissue ACE.

REFERENCES